Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines

References

• Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993; 53: 5970–6.
   PubMed Web of Science ®Google Scholar
• Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetra-platin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochern Pharrnacol 1996; 52: 1855–65.
   Google Scholar
• Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Therap 2002; 1: 227–35.
   PubMed Web of Science ®Google Scholar
• Rietbroek RC, Van de Vaart PJ, Haveman J, Blommaert FA, Geerdink A, Bakker PJ, Veenhof CH. Hyperthermia enhances the cytotoxicity and platinum—DNA adduct forma-tion of lobaplatin and oxaliplatin in cultured sw 1573 cells. J Cancer Res Clin Oncol 1997; 123: 6–12.
   PubMed Web of Science ®Google Scholar
• Westermann AM, Grosen EA, Katschinski DM, Jager D, Rietbroek R, Schink JC, Tiggelaar CL, Jager E, Zum Vorde sive Vording P, Neuman A, Knuth A, Van Dijk JD, Wiedemann GJ, Robins HI. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. Eur J Cancer 2001; 37: 1111–17.
   Google Scholar
• Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001; 7: 2168–81.
   PubMed Web of Science ®Google Scholar
• Nitta M, Okamura H, Aizawa S, Yamaizumi M. Heat shock induces transient p53-dependent cell cycle arrest at G1/S. Oncogene 1997; 15: 561–8.
   PubMed Web of Science ®Google Scholar
• Kuhl NM, Rensing L. Heat shock effects on cell cycle progression. Cell Mol Life Sci 2000; 57: 450–63.
   PubMed Web of Science ®Google Scholar
• Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988; 48: 4484–8.
   PubMed Web of Science ®Google Scholar
• Nguyen RN, Sevin BU, Averette HE, Perras J, Ramos R, Donato D, Ochiai K, Penalver M. Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines. Cancer Invest 1993; 11: 264–75.
   PubMed Web of Science ®Google Scholar
• Nguyen RN, Sevin B, Averette HE, Donato D, Ramos R, Penalver M. Comparison of cytotoxicity and cell kinetic perturbations of five platinum compounds in gynecologic cancer cell lines. Int J Oncol 1993; 3: 375–82.
   PubMed Web of Science ®Google Scholar
• Kuang J, He G, Huang Z, Khokhar AR, Siddik ZH. Bimodal effects of 1R,2R-diamino-cyclohexane(trans-diacetato)(dichloro) platinum(IV) on cell cycle checkpoints. Clin Cancer Res 2001; 7: 3629–39.
   Google Scholar
• Fischel JL, Formento P, Ciccolini J, Rostagno P, Etienne MC, Catalin J, Milano G. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellu-lar determinants of drug activity. Br J Cancer 2002; 86: 1162–8.
   Google Scholar
• Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, Riou G. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985; 45: 4970–9.
   PubMed Web of Science ®Google Scholar
• Van Bree C, Franken NA, Snel FA, Haveman J, Bakker PJ. Wild-type P53-function is not required for hyperthermia-enhanced cytotoxicity of cisplatin. Int J Hypertherrnia 2001; 17: 337–46.
   Google Scholar
• Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Volgelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497–501.
   Google Scholar
• Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–30.
   PubMed Web of Science ®Google Scholar
• Perez-Roger I, Solomon DL, Sewing A, Land H. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of P27(Kipl) binding to newly formed complexes. Oncogene 1997; 14: 2373–81.
   Google Scholar
• Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-cdk4 and -cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999; 19: 4672–83.
   Google Scholar
• Muller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R, Ansorge W, Huttner W, Eilers M. Cdk2-dependent phosphorylation of p27 facilitates its myc-induced release from cyclin E/cdk2 complexes. Oncogene 1997; 15: 2561–76.
   Google Scholar
• Yang W, Shen J, Wu M, Arsura M, Fitzgerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romica-Mourez R, Freedman LP, Sonenshein GE. Repression of transcription of the p27(Kipl) cyclin-dependent kinase inhibitor gene by c-myc. Oncogene 2001; 20: 1688–702.
   Google Scholar
• Van De Vaart PJ, Van Der Vange N, Zoetmulder FA, Van Goethem AR, Van Tellingen O, Ten Bokkel Huinink WW, Beijnen JR, Bartelink H, Begg AC. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34: 148–54.
   PubMed Web of Science ®Google Scholar
• Van Der Vange N, Van Goethem AR, Zoetmulder FA, Kaag MM, Van De Vaart PJ, Ten Bokkel Huinink WW, Beijnen JR. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000; 26: 663–8.
   PubMed Web of Science ®Google Scholar
• Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by com-plete resection and intraperitoneal chemotherapy. Cancer 2001; 92: 71–6.
   PubMed Web of Science ®Google Scholar
• Rossi CR, Foletto M, Mocellin S, Pilati P, De Simone M, Deraco M, Cavalière F, Palatini P, Guasti F, Scalerta R, Lise M. Hyperthermic intraoperative intraperitoneal chemother-apy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 2002; 94: 492–9.
   Google Scholar
• Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El Otmany A, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M. Heated intra-operative intraperitoneal oxa-liplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002; 13: 267–72.
   Google Scholar
• Ohno S, Siddik ZH, Kido Y, Zwelling LA, Bull JM. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chernother Pharrnacol 1994; 34: 302–6.
   Google Scholar
• Wallner KE, Li GC. Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. Cancer Res 1987; 47: 493–5.
   PubMed Web of Science ®Google Scholar
• Kusumoto T, Maehara Y, Baba H, Takahashi I, Kusumoto H, Ohno S, Sugimachi K. Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxi-city and intracellular platinum accumulation in HeLa cells. Br J Cancer 1993; 68: 259–63.
   Google Scholar
• Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hypertherrnia 1999; 15: 79–107.
   Google Scholar
• Dewhirst MW, Prosnitz L, Thrall D, Prescott D, Clegg S, Charles C, MacFall J, Rosner G, Samulski T, Gillette E, LaRue S. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Sernin Oncol 1997; 24: 616–25.
   Google Scholar
• Sanderson BJ, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat Res 1996; 355: 59–70.
   Google Scholar
• Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers LC, Rossi J. Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res 1989; 9: 1301–12.
   PubMed Web of Science ®Google Scholar
• Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hernatol 2000; 35: 75–93.
   PubMed Web of Science ®Google Scholar
• Andrews PA. Mechanisms of acquired resistance to cisplatin. In: Ozols RF, Goldstein Li, eds. Drug Resistance. Boston: Kluwer, 1994; 217–48.
   Google Scholar
• Chaney SG. The chemistry and biology of platinum complexes with the 1,2-diamino-cyclohexane carrier ligand (review). Int J Oncol 1995; 6: 1291–305.
   PubMed Web of Science ®Google Scholar
• Weiss RB, Christian MC. New cisplatin analogues in development: a review. Drugs 1993; 46: 360–77.
   PubMed Web of Science ®Google Scholar
• Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053–71.
   PubMed Web of Science ®Google Scholar
• Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res 1998; 4: 1021–9.
   Google Scholar
• Tassone P, Tagliaferri P, Galea E, Palmieri C, Bonelli P, Martelli ML, Tucillo F, Turco MC, Venuta S. Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. Eur J Cancer 2002; 38: 1141–7.
   Google Scholar
• Mishima M, Samimi G, Kondo A, Lin X, Howell SB. The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 2002; 38: 1405–12.
   PubMed Web of Science ®Google Scholar
• Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE. Oxaliplatin-induced damage of cellular DNA. Mol Pharrnacol 2000; 58: 920–7.
   Web of Science ®Google Scholar
• Cohen JD, Robins HI, Schmitt CL. Tumoricidal interactions of hyperthermia with carboplatin, cisplatin and etoposide. Cancer Lett 1989; 44: 205–10.
   Google Scholar
• Cohen JD, Robins HI. Thermal enhancement of tetraplatin and carboplatin in human leukaemic cells. Int J Hypertherrnia 1990; 6: 1013–17.
   PubMed Web of Science ®Google Scholar
• Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8: 876–85.
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hernatol 2002; 43: 33–56.
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672–7.
   PubMed Web of Science ®Google Scholar
• Hunter T, Pines J. Cyclins and cancer. Cell 1991; 66: 1071–4.
   PubMed Web of Science ®Google Scholar
• O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace Ai, Jr., Kohn KW. Characterization of the P53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285–300.
   PubMed Web of Science ®Google Scholar
• Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997; 16: 5334–44.
   Google Scholar
• Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18: 753–61.
   PubMed Web of Science ®Google Scholar
• Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004–16.
   PubMed Web of Science ®Google Scholar
• Biroccio A, Benassi B, Amodei S, Gabellini C, Del Bufalo D, Zupi G. C-myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. Mol Pharrnacol 2001; 60: 174–82.
   PubMed Web of Science ®Google Scholar
• Erisman MD, Rothberg PG, Diehl RE, Morse CC, Spandorfer JM, Astrin SM. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol Cell Biol 1985; 5: 1969–76.
   PubMed Web of Science ®Google Scholar
• Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001; 61: 4910–15.
   Google Scholar
• Djelloul S, Forgue-Lafitte ME, Hermelin B, Mareel M, Bruyneel E, Baldi A, Giordano A, Chastre E, Gespach C. Enterocyte differentiation is compatible with 5V40 large T expres-sion and loss of p53 function in human colonic Caco-2 cells, status of the pRbl and pRb2 tumor suppressor gene products. FEBS Lett 1997; 406: 234–42.
   PubMed Web of Science ®Google Scholar